Abstract
Introduction
Datamonitor expects the Australian antidiabetics market to reach $416m by
2018. The growth will be driven by the launch of new drug classes, notably the
incretin mimetics, and large growth in patient numbers. Although strongest
growth is expected in the non-insulin market, the insulin market will continue
to dominate, generating revenues of $224m 10 years from now.
Scope of this research
- Forecast for marketed and late-stage pipeline antidiabetic products in
Australia
- Assessment of Australia-specific drivers and resistors likely to impact
the market
- Future market outlook for individual products taking into account key
market events, in particular patent expiry and competitor launch dates
- Case study examining the approval and reimbursement process in Australia
in general and for several antidiabetics in specific
Research and analysis highlights
The Australian antidiabetics market is expected to grow from $233m in 2008 to
$416m in 2018 at a rate of 6% CAGR. Significant unmet needs in diabetes fuel a
large pipeline. The epidemiological growth of the market, impacted by the
obesity epidemic and improved diagnosis rates, is further driving the market.
In 2008, the long- and fast-acting insulin classes dominated the insulin
market. This situation is not expected to change throughout the forecast
period as there is very limited activity within the insulin antidiabetic
pipeline and no serious challenges to the market leading therapies.
The strong market position of Avandia in 2007 has all but been destroyed by a
meta-analysis published in mid-2007. Despite positive outcomes from
GlaxoSmithKline' s RECORD trial in 2009, the product will not regain market
share before its patent expiry.
Key reasons to purchase this research
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the Australian antidiabetics market
and predict the performance of key compounds
- Understand critical success factors in growing and defending antidiabetic
brand franchises from new entrants and generics
| 
View Cart
